Alchemia looks to FDA after positive end to HyCAMP trial

Australia's Alchemia says it plans to discuss the progress of its colorectal cancer drug HyCAMP after successfully wrapping a mid-stage trial of the therapy. Eighty patients in the trial were treated with either HyCAMP or Camptosar. Researchers say that patients in the trial were able to remain on HyCAMP longer due to reduced toxicity and increased efficacy.

"The fact that we are seeing statistically significant improvements in efficacy end-points from such a small study is a reflection of the substantial increase in anti-tumor activity seen with HyCAMP," says CEO Dr Peter Smith. "Generally, much larger studies would be required to show such effects. This data is an exceptional validation of our HyACT drug delivery technology platform and its application to the treatment of cancer patients."

- check out the release for more information

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.